Objective: To assess whether the use of assisted reproductive technology (ART) therapy for conception is associated with imprinting disorders in children and the impact of parental factors related to infertility., Design: A nationwide register-based cohort study., Setting: Swedish national registers and nationwide quality IVF register., Patient(s): All liveborn singletons in Sweden (N = 2,084,127) between 1997 and 2017 with follow-up to December 31, 2018., Intervention(s): The use of specific methods implemented in ART., Main Outcome Measure(s): The International Classification of Diseases version 10 was used to identify three distinct imprinting disorder groups: Beckwith-Wiedemann syndrome (BWS), Prader-Willi syndrome (PWS), and Silver-Russell syndrome (SRS), as well as central precocious puberty. The Cox model combined with inverse probability treatment weights was used to estimate the weighted hazard ratio (wHR) with a 95% confidence interval (CI), accounting for multiple confounders., Result(s): A total of 1,044 children were diagnosed with the disorders of interest, and 52 of them were conceived using ART therapy. The overall risk of being diagnosed with any of the studied imprinting disorders was elevated in children conceived using ART therapy compared with all other children (HR, 1.84; 95% CI, 1.38-2.45). After adjusting for parental background factors, the association was partially attenuated (wHR, 1.50; 95% CI, 0.97-2.32), but remained in the weighted comparison restricted to children of couples with known infertility (wHR, 1.52; 95% CI, 1.05-2.21). For the specific diagnoses of PWS/SRS, and BWS compared with children of couples with known infertility, children conceived with ART therapy showed a small excess risk, which could not be distinguished from the null (wHR, 1.56; 95% CI, 0.93-2.62 and 1.80; 95% CI, 0.99-3.28, respectively). Further subgroup analysis showed that the combined use of intracytoplasmic sperm injection and cryopreserved embryos was associated with a higher risk of both PWS/SRS (wHR, 4.60; 95% CI, 1.72-12.28) and BWS (wHR, 6.69; 95% CI, 2.09-21.45). The number of central precocious puberty cases in children conceived using ART therapy was too small (N = 3) to make any meaningful inference., Conclusion(s): The combined use of intracytoplasmic sperm injection and cryopreserved embryos was associated with small elevated risks of PWS/SRS, and BWS in children, independent of parental factors related to infertility., Competing Interests: Declaration of Interests M.Y. reports funding from the Chinese Scholarship Council for the submitted work. A.R.P. has nothing to disclose. E.I. reports funding from grants from Stockholm County Council (FoUI-961392) and Karolinska Institutet; Merck; honoraria for lectures; Illumina; payment for lectures; and travel costs to the conference outside the submitted work. A.S.O. reported grants from the National Institutes of Health and the Swedish Council for Working Life and Social Welfare during the conduct of the study and personal fees from Abbott (the Scientific and Medical Advisory Council) outside the submitted work. K.A.R.W. reports funding from the Swedish Research Council, the Swedish Cancer Society grants, the Swedish Childhood Cancer Fund, Radiumhemmets Forskningsfonder, Stockholm County Council Research and Development FoU grants, Karolinska Institutet, IngaBritt och Arne Lundbergs Forskningsstiftelse, and Stockholm County Council for the submitted work; funding from Foundation Stiftelse Bert Lundins minne grant 2022 and Research grants from NovoNordisk, Merck, Gedeon Richter and Ferrring Pharmaceuticals; royalties from YES Student Litteratur, Sweden, author of chapter in medical text book; consulting fees from The Swedish Ministry of Health and Welfare as expert in assisted reproduction and fertility preservation for transgender people; honoraria from Roche for chairmanship and lectures for education of oncologists, honoraria from Pfizer for chairmanship and lectures for education of oncologists, honoraria from Organon for lectures for obstetricians or gynecologists and reproductive medicine specialists, honoraria from IBSA for Advisory Board for educational event; support from Organon for participation in Journées Fertilité 2023, Paris, France; support from Regionstockholm for participation as chair of the Swedish Interest Group in Reproductive Medicine Fert-ARG, for the Swedish Society of Obstetrics and Gynecology (SFOG); participation at the advisory board for Merck, Nordic countries, and participation at the advisory board for Ferring, National Coordinator of Study; time-lapse equipment for preclinical research from Merck Pharmaceuticals, unrestricted grant; grant for experimental in vitro research from Ferring Pharmaceuticals, an unrestricted grant outside the submitted work., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)